Form 8-K - Current report:
SEC Accession No. 0001753926-25-000984
Filing Date
2025-06-20
Accepted
2025-06-20 16:02:53
Documents
13
Period of Report
2025-06-20
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K g084852_8k.htm   iXBRL 8-K 43597
2 PRESS RELEASE g084852_ex99-1.htm EX-99.1 11416
  Complete submission text file 0001753926-25-000984.txt   223883

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE lipo-20250620.xsd EX-101.SCH 3011
4 XBRL LABEL FILE lipo-20250620_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE lipo-20250620_pre.xml EX-101.PRE 22356
15 EXTRACTED XBRL INSTANCE DOCUMENT g084852_8k_htm.xml XML 3518
Mailing Address 400 N LEXINGTON ST STE LL103 PITTSBURGH PA 15208
Business Address 400 N LEXINGTON ST STE LL103 PITTSBURGH PA 15208 412-901-0315
LIPELLA PHARMACEUTICALS INC. (Filer) CIK: 0001347242 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41575 | Film No.: 251061252
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)